Cardiovascular toxicity profiles of vascular-disrupting agents.

ABSTRACT:

Background

Vascular-disrupting agents (VDAs) represent a new class of chemotherapeutic agent that targets the existing vasculature in solid tumors. Preclinical and early-phase trials have demonstrated the promising therapeutic benefits of VDAs but have also uncovered a distinctive toxicity profile highlighted by cardiovascular events.

Methods

We reviewed all preclinical and prospective phase I-III clinical trials published up to August 2010 in MEDLINE and the American Association of Cancer Research and American Society of Clinical Oncology meeting abstracts of small-molecule VDAs, including combretastatin A4 phosphate (CA4P), combretastatin A1 phosphate (CA1P), MPC-6827, ZD6126, AVE8062, and ASA404.

Results

Phase I and II studies of CA1P, ASA404, MPC-6827, and CA4P al

SUBMITTER: Subbiah IM 

PROVIDER: S-EPMC3228163 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature